Details of the Drug
General Information of Drug (ID: DMHQDLX)
| Drug Name |
EPO-derived peptide
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
EPO-derived peptide (diabetic retinopathy); EPO helix-B domain peptide (diabetic retinopathy), Araim Pharmaceuticals; EPO-derived peptide (diabetic retinopathy), Araim Pharmaceuticals; Erythropoietin-derived peptide (diabetic retinopathy), Araim Pharmaceuticals
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Diabetic retinopathy | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | 9B71.0 | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||

